• Citer

Study protocol for THINK: A multinational open-label phase i study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

par Lonez, Caroline ;Verma, B.;Hendlisz, Alain ;Aftimos, Philippe ;Awada, Ahmad ;Van Den Neste, Eric;Catala, Gaetan;Machiels, Jean Pascal J.P.H.;Piette, Fanny;Brayer, Jason J.B.;Sallman, David D.A.;Kerre, Tessa;Odunsi, K.;Davila, Marco M.L.;Gilham, D.E.;Lehmann, F.F.
Référence BMJ open, 7, 11, e017075
Publication Publié, 2017-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Study protocol for THINK: A multinational open-label phase i study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
Auteur:	Lonez, Caroline; Verma, B.; Hendlisz, Alain; Aftimos, Philippe; Awada, Ahmad; Van Den Neste, Eric; Catala, Gaetan; Machiels, Jean Pascal J.P.H.; Piette, Fanny; Brayer, Jason J.B.; Sallman, David D.A.; Kerre, Tessa; Odunsi, K.; Davila, Marco M.L.; Gilham, D.E.; Lehmann, F.F.
Informations sur la publication:	BMJ open, 7, 11, e017075
Statut de publication:	Publié, 2017-11
Sujet CREF:	Droit
Mots-clés:	car-t
	chimeric antigen receptor
	multiple injections
	nkg2d
	nkr-2
	solid tumours
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2044-6055
	info:doi/10.1136/bmjopen-2017-017075
	info:scp/85043324884
	info:pmid/29133316